CD25/IL-2R alpha Antibody (Basiliximab) - Chimeric - Azide and BSA Free

Immunohistochemistry: CD25/IL-2R alpha Antibody (Basiliximab) - Chimeric [NBP2-75902] - Formalin fixed rat spleen slices were were stained with a NBP2-75902 at 5 ug/ml. The anti-human CD25 antibody NBP2-75902 also shows some cross-reactivity with rat in IHC.

Immunocytochemistry/Immunofluorescence: CD25/IL-2R alpha Antibody (Basiliximab) - Chimeric [NBP2-75902] - Formaldehyde-fixed rat thymus slices were stained with NBP2-75902 at 5 ug/ml and detected with a FITC-conjugated secondary antibody. Ab00188 shows weak labelling of rat cells by IF.

Western Blot: CD25/IL-2R alpha Antibody (Basiliximab) - Chimeric - Azide and BSA Free [NBP2-75902] - Human thyroid cancer (lane 1), rat spleen (lane 2), mouse lymph node (lane 3), mouse thymus (lane 4) and rat small intestines (lane 5) samples were resolved on a 10% SDS PAGE gel and blots probed with NBP2-75902 at 1 ug/ml before being detected by a secondary antibody.

• Reactivity: Hu, Pm-Cm, RM
• Applications: WB, Flow, ICC/IF, IHC, B/N
• Clone: Basiliximab
• Clonality: Monoclonal
• Host: Human
• Conjugate: Unconjugated
• Format: Azide and BSA Free
• Concentration: 1 mg/ml

CD25/IL-2R alpha Antibody (Basiliximab) - Chimeric - Azide and BSA Free Summary

• Description: Novus Biologicals Human CD25/IL-2R alpha Antibody (Basiliximab) - Chimeric - Azide and BSA Free (NBP2-75902) is a monoclonal antibody validated for use in IHC, WB, Flow and ICC/IF. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Immunogen: Basiliximab was prepared by immunizing BALB/c mice with CTC 16 cells.
• Specificity: Basiliximab recognises the human IL-2R and binds to the epitope (116)ERIYHFV(122) within the extracellular domain of the CD25 subunit -binding is abolished when 2 or more residues within the epitope are mutated. This epitope overlaps with the interaction site of CD25 and IL-2. CD25 is found in the high-affinity IL-2R ((alpha)(beta)(gamma)c) -T cells only express CD25 upon activation. IL-2 binding to IL-2R on T cells modulates proliferation and differentiation.
• Isotype: IgG1 Kappa
• Clonality: Monoclonal
• Host: Human
• Gene: IL2RA
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • Block/Neutralize
  • Flow Cytometry
  • Immunocytochemistry/ Immunofluorescence
  • Immunohistochemistry
  • Western Blot
• Application Notes: NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques.

Packaging, Storage & Formulations

• Storage: Store at 4C for up to 3 months. For longer storage, aliquot and store at -20C.
• Buffer: PBS
• Preservative: 0.02% Proclin 300
• Concentration: 1 mg/ml
• Purity: Protein A purified

Alternate Names for CD25/IL-2R alpha Antibody (Basiliximab) - Chimeric - Azide and BSA Free

• biosimilar antibody
• biosimilars
• CD25 antigen
• CD25
• IDDM10
• IL-2 R alpha
• IL-2 receptor subunit alpha
• IL2R alpha
• IL-2R subunit alpha
• IL2R
• IL2RA
• IL-2Ra
• IL-2-RA
• IL2-RA
• interleukin 2 receptor, alpha
• interleukin-2 receptor subunit alpha
• p55
• TAC antigen
• TCGFR

Background

The interleukin 2 (IL2) receptor alpha (IL2RA) and beta (IL2RB) chains, together with the common gamma chain (IL2RG), constitute the high-affinity IL2 receptor. Homodimeric alpha chains (IL2RA) result in low-affinity receptor, while homodimeric beta (IL2RB) chains produce a medium-affinity receptor. Normally an integral-membrane protein, soluble IL2RA has been isolated and determined to result from extracellular proteolyisis. Alternately-spliced IL2RA mRNAs have been isolated, but the significance of each is presently unknown. Mutations in this gene are associated with interleukin 2 receptor alpha deficiency.(provided by RefSeq)

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: IL2RA